Eiji Higashihara

Mitaka, 1818611, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial.

Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial.

Journal: Clinical and experimental nephrology

Published: July 30, 2024

Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease.

Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease.

Journal: Expert opinion on pharmacotherapy

Published: May 22, 2024

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD.

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD.

Journal: Kidney international reports

Published: August 03, 2021

PKD1-Associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease.

PKD1-Associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease.

Journal: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Published: March 24, 2021

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.

Journal: BMC medical genomics

Published: March 02, 2021

Pigmented median raphe cyst of the penis that developed after middle age without infection or trauma history.

Pigmented median raphe cyst of the penis that developed after middle age without infection or trauma history.

Journal: IJU case reports

Published: January 27, 2021

Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.

Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.

Journal: American journal of nephrology

Published: August 01, 2020

Estimation of Changes in Kidney Volume Growth Rate in ADPKD.

Estimation of Changes in Kidney Volume Growth Rate in ADPKD.

Journal: Kidney international reports

Published: January 22, 2020

Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma.

Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma.

Journal: BMC urology

Published: October 15, 2019

Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report.

Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report.

Journal: Journal of medical case reports

Published: May 17, 2019

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Journal: Kidney international

Published: June 08, 2018

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.

Journal: Clinical and experimental nephrology

Published: May 02, 2018

Showing 1-12 of 39

Last Updated: 09/26/2026